Melior Discovery
Dr. Gruner directs all neurophysiology studies at Melior. He specializes in working with clients to custom-design experiments to evaluate therapeutic efficacy in models of motoneuron disease (e.g. G93A transgenic SOD mice), neurotrauma, pain and muscle relaxation (nociceptive and proprioceptive spinal reflexes and neuromuscular function), sleep / wake and general cortical function (including high-frequency EEG analysis and evoked potentials), and EEG-based pro- and anti-convulsant evaluation.
During his 19 years at Cephalon, Inc., he designed and supervised neurophysiological and pharmacological studies involving numerous disease areas, including evaluation of neuroprotection by trophic agents, free radical inhibitors, kinase inhibitors, and other compounds in neuropathy, neurodegeneration, and motor neuron disease models. He has also elucidated mechanisms of action of proprietary analgesic agents and utilized evoked potentials for evaluating functional impairment in models of cognitive disorders such as schizophrenia.
This person is not in any offices
Melior Discovery
Melior Discovery Inc (Exton, PA, USA) has pioneered a unique “high throughput” in vivo pharmacology platform (theraTRACE®) able to systematically identify novel indications for pre-clinical and development-stage drugs.